A Vera de Jonge (A V de Jonge)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Diffuse Large B Cell Lymphoma

Prognostic Factors

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
A Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, Charlotte L B M Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein W M van der Poel, Koen de Heer, Clara P W Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R Koene, Margaretha G M Roemer, Erik D van Werkhoven, Martine E D Chamuleau, Tuna Mutis
Distinct Peripheral T-cell and NK-cell Profiles In HGBL-MYC/BCL2 versus DLBCL NOS Patients. Blood advances (2024)
A Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, Charlotte L B M Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein W M van der Poel, Koen de Heer, Clara P W Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R Koene, Margaretha G M Roemer, Erik D van Werkhoven, Martine E D Chamuleau, Tuna Mutis
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS. Blood advances 8 (5) (2024)
A Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, Charlotte L B M Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein W M van der Poel, Koen de Heer, Clara P W Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R Koene, Margaretha G M Roemer, Erik D van Werkhoven, Martine E D Chamuleau, Tuna Mutis
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS. Blood advances 8 (5) (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
A Vera de Jonge, J A A Bult, D F E Karssing, Marcel Nijland, Martine E D Chamuleau, Mirian Brink
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. Blood cancer journal 14 (1) (2024)
A Vera de Jonge, Erik D van Werkhoven, Avinash G Dinmohamed, Marcel Nijland, Aeilko H Zwinderman, Patrick M Bossuyt, Martine S Veldhuis, Emma G G M Rutten, Rogier Mous, Joost S P Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M Bilgin, Rinske Boersma, Harry Koene, Marie José Kersten, Daphne de Jong, Martine E D Chamuleau
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients. Blood cancer journal 13 (1) (2023)
Hilma J van der Horst, A Vera de Jonge, Ida H Hiemstra, Anne T Gelderloos, Daniella R A I Berry, Nathalie J Hijmering, Hendrik F van Essen, Daphne de Jong, Martine E D Chamuleau, Sonja Zweegman, Esther C W Breij, Margaretha G M Roemer, Tuna Mutis
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood cancer journal 11 (2) (2021)
A Vera de Jonge, Tuna Mutis, Margaretha G M Roemer, Blanca Scheijen, Martine E D Chamuleau
Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. Cancers 12 (10) (2020)